A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
Author:
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s40258-019-00513-3.pdf
Reference19 articles.
1. American Cancer Society. Global cancer facts & figures. 4th ed. Atlanta: American Cancer Society; 2018.
2. Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Mak. 2005;25:520–33. https://doi.org/10.1177/0272989X05280561 .
3. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:1295–310. https://doi.org/10.1002/hec.1148 .
4. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M, ISPOR-SMDM Modeling Good Research Practices Task Force. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Mak. 2012;32:678–89. https://doi.org/10.1177/0272989X12454941 .
5. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–50. https://doi.org/10.1016/j.jval.2013.02.002 .
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care;PharmacoEconomics;2024-09-07
2. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT;Health Technology Assessment;2024-08
3. Cost–effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer;Immunotherapy;2024-05-22
4. Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit;Applied Health Economics and Health Policy;2024-05-21
5. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost‐effectiveness analysis;Cancer Medicine;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3